How to Pay for Transformative Cell and Gene Therapies

Posted by Bernadette Bourjolly on Oct 13, 2017 8:00:00 AM

Malik Kaman co-wrote this blog post with Bernadette Bourjolly. 

After two decades of failures and setbacks, it’s an exciting time in the field of cell and gene therapies as we witness pioneering advances in a wide range of indications in areas including blood cancers, immunodeficiency and ophthalmology. While cell and gene therapies represent a potential paradigm shift for the treatment of cancer and rare genetic disorders, funding and reimbursement of these unconventional therapies pose major challenges. 


>
Read More

ESMO 2017: Examining New Models to Define, Measure and Pay for Value

Posted by Richard Secker-Johnson on Sep 27, 2017 11:08:36 AM

Can true value-based pricing ever be a reality in Europe? If the answer is no, we may well be headed towards a price/access “crisis” as rising oncology costs continue to outstrip country healthcare budgets. If the answer is yes, it certainly seems like there’s still a long way to go.


>
Read More